Healthcare • NYSE
According to Zyberno, ARTIVION, INC. (AORT) is not a buy — POOR BUSINESS (29/100) with a negative Margin of Safety of -9.9% and a Brina Gap of -27.6% showing the market already prices in more growth than the fundamentals support.
According to Zyberno's DCF model, ARTIVION, INC. (AORT) trades at $26.77 against an estimated intrinsic value per share of $24.36 — a -9.9% Margin of Safety based on Owner Earnings of $37.99M TTM, projected at 90.1% growth for 10 years with a 2.5% terminal growth rate. The Brina Gap of -27.6% weakens the case: based on the company's ROIC (2.1%) and reinvestment rate (107.1%), the business can fundamentally grow at 2.3% — but the current enterprise value implies the market expects 29.8%. This places AORT in the Expensive Hype quadrant of the Brina Matrix, the most fragile combination — overvalued on cash AND overpriced on growth. Zyberno's model translates this into a 5-year expected return of 17.8% annually.
Over the trailing twelve months, AORT generated $37.99M in Owner Earnings. Capital was deployed as follows: $43.41M invested in capital expenditures. Reinvestment rate: 107.1%. Owner Earnings have grown at 90.1% annually over the trailing five years using log-linear regression.